At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
RC18 160mg +2 morebiological
Likely dose
RC18 160mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial of RC18(Recombinant Human B Lymphocyte Stimulator Receptor - Antibody Fusion Protein for Injection) in the Treatment of Primary IgA Nephropathy
In Brief
A Phase 2 clinical trial evaluating RC18 160mg, RC18 240mg, and 1 other intervention for Primary IgA Nephropathy. Completed, enrolled 44 participants across 1 site.
Detailed Summary
To evaluate the safety and efficacy of Tai Ai(Recombinant Human B Lymphocyte Stimulator Receptor-Antibody Fusion Protein for Injection) in the treatment of IgA nephropathy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary IgA Nephropathy
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 2020
Enrollment StartApr 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedMar 2, 2020
Enrollment StartApr 13, 2020
Primary CompletionMay 20, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.3 years ago
Interventions
RC18 160mgbiological
subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
RC18 240mgbiological
subcutaneous injection on the upper arm, abdomen, or upper thigh outside;
placebobiological
subcutaneous injection on the upper arm, abdomen, or upper thigh outside;